Abstract:Multiple myeloma (MM) is a highly heterogeneous hematological malignancy that is currently incurable. Individualized therapeutic approaches based on accurate risk assessment are essential for improving the prognosis of MM patients. Nevertheless, current prognostic models for MM exhibit certain limitations and prognosis heterogeneity still an unresolved issue. Recent studies have highlighted the pivotal involvement of mitochondrial autophagy in the development and drug sensitivity of MM. This study seeks to conduct an integrative analysis of the prognostic significance and immune microenvironment of mitophagy-related signature in MM, with the aim of constructing a novel predictive risk model. GSE4581 and GSE47552 datasets were acquired from the Gene Expression Omnibus database. MM-differentially expressed genes (DEGs) were identified by limma between MM samples and normal samples in GSE47552. Mitophagy key module genes were obtained by weighted gene co-expression network analysis in the Cancer Genome Atlas (TCGA)-MM dataset. Mitophagy DEGs were identified by the overlap genes between MM-DEGs and mitophagy key module genes. Prognostic genes were selected through univariate Cox regression and least absolute shrinkage and selection operator (LASSO) analysis, and a risk model was subsequently constructed based on these prognostic genes. Subsequently, the MM samples were stratified into high- and low-risk groups based on their median risk scores. The validity of the risk model was further evaluated using the GSE4581 dataset. Moreover, a nomogram was developed using the independent prognostic factors identified from the risk score and various clinical indicators. Additionally, analyses were conducted on immune infiltration, immune scores, immune checkpoint, and chemotherapy drug sensitivity. The 17 mitophagy DEGs were obtained by intersection of 803 MM-DEGs and 1084 mitophagy key module genes. Five prognostic genes (CDC6, PRIM1, SNRPB, TOP2A, and ZNF486) were selected via LASSO and univariate cox regression analyses. The predictive performance of the risk model, which was constructed based on the five prognostic genes, demonstrated favorable results in both TCGA-MM and GSE4581 datasets as indicated by the receiver operating characteristic (ROC) curves. In addition, calibration curve, ROC curve, and decision curve analysis curve corroborated that the nomogram exhibited superior predictive accuracy for MM. Furthermore, immune analysis results indicated a significant difference in stromal scores of two risk groups categorized on median risk scores. And four immune checkpoints (CD274, CTLA4, LAG3, and PDCD1LG2) showed significant differences in different risk groups. The analysis of chemotherapy drug sensitivity revealed that etoposide and doxorubicin, which target TOP2A , exhibited superior treatment outcomes in the high-risk group. A novel prognostic model for MM was developed and validated, demonstrating significant potential in predicting patient outcomes and providing valuable guidance for personalized immunotherapy counseling.

Characterization and application of a lactate and branched chain amino acid metabolism related gene signature in a prognosis risk model for multiple myeloma

Additional File 3 of Characterization and Application of a Lactate and Branched Chain Amino Acid Metabolism Related Gene Signature in a Prognosis Risk Model for Multiple Myeloma

A novel glycolysis-related gene signature for predicting the prognosis of multiple myeloma

An emerging prognosis prediction model for multiple myeloma: Hypoxia-immune related microenvironmental gene signature

Identification of a novel lactylation-related gene signature predicts the prognosis of multiple myeloma and experiment verification

Identification and Validation of a Novel RNA-Binding Protein-Related Gene-Based Prognostic Model for Multiple Myeloma

One-lincRNA and Five-Mrna Based Signature for Prognosis of Multiple Myeloma Patients Undergoing Proteasome Inhibitors Therapy

Developing mRNA signatures as a novel prognostic biomarker predicting high risk multiple myeloma

Identification of lipid metabolism-related gene signature in the bone marrow microenvironment of multiple myelomas through deep analysis of transcriptomic data

Identifying the prognostic significance of mitophagy-associated genes in multiple myeloma: a novel risk model construction

Identification of an Autophagy-Related Signature Based on Whole Bone Marrow Sequencing for the Prognosis and Immune Microenvironment Characterization of Multiple Myeloma

Mitophagy-related gene signature for predicting the prognosis of multiple myeloma

A novel risk score model of lactate metabolism for predicting outcomes and immune signatures in acute myeloid leukemia

Characterization of a Lactate Metabolism-Related Signature for Evaluation of Immune Features and Prediction Prognosis in Glioma.

Construction of mitochondrial quality regulation genes‐related prognostic model based on bulk‐RNA‐seq analysis in multiple myeloma

Prediction of prognosis and immunotherapy response of amino acid metabolism genes in acute myeloid leukemia

A novel ferroptosis-related gene signature for predicting prognosis in multiple myeloma

Amino Acid Metabolism-Related lncRNA Signature Predicts the Prognosis of Breast Cancer

[Prognosis and immune biomarkers of multiple myeloma]

Identification and validation of a cellular senescence-related lncRNA signature for prognostic prediction in patients with multiple myeloma

An inflammatory response-related gene signature can predict the prognosis and impact the immune infiltration of multiple myeloma